HomeGeneticsGeneCDKN1B gene
Back to Gene
CDKN1B gene
Reviewed by Medicinsk Expert•Last updated: 2026-10-22•Gene

CDKN1B gene

The CDKN1B gene produces the p27 protein, a tumor suppressor that regulates the cell cycle and prevents uncontrolled cell division.

Normal Function

The CDKN1B gene provides instructions for making a protein called p27. Located primarily in the cell nucleus, p27 acts as a tumor suppressor by blocking cells from entering the phase of the cell cycle where DNA is replicated. By regulating this cycle, p27 prevents cells from dividing too quickly or at the wrong time. It is also involved in cell differentiation. The activity of p27 is tightly regulated; if it is sequestered in the cytoplasm instead of the nucleus, it cannot perform its function of blocking cell cycle progression.

Health Conditions Related to Genetic Changes

Multiple endocrine neoplasia

Mutations in the CDKN1B gene cause a rare form of multiple endocrine neoplasia called type 4. This condition involves the development of tumors in hormone-producing glands, most commonly the parathyroid and pituitary glands. These mutations reduce the amount of functional p27 available in the nucleus, allowing cells to divide in an uncontrolled way and form tumors.

Other tumors

Somatic mutations (not inherited) in the CDKN1B gene have been identified in sporadic pituitary adenomas and sporadic parathyroid adenomas. Additionally, while the gene is rarely mutated in other cancers, a reduction in the amount or function of the p27 protein is often associated with more aggressive tumors and a poorer prognosis in many types of cancer.

Other Names for This Gene

  • CDKN4
  • CDN1B_HUMAN
  • cyclin-dependent kinase inhibitor 1B
  • cyclin-dependent kinase inhibitor 1B (p27, Kip1)
  • KIP1
  • MEN1B
  • MEN4
  • P27KIP1

Frequently Asked Questions

Guidelines recommend annual biochemical testing—serum calcium and PTH for parathyroid disease, and prolactin, IGF‑1, and cortisol for pituitary function—plus imaging (neck ultrasound for parathyroids, MRI of the pituitary) every 1–2 years, starting in early adolescence. Screening should be coordinated by an endocrinologist familiar with MEN syndromes.
CDKN1B mutations are inherited in an autosomal‑dominant manner, meaning each child has a 50 % chance of inheriting the variant. Both males and females are equally affected, and penetrance is high for endocrine tumors, so predictive testing is offered to at‑risk relatives.
While lifestyle cannot prevent the genetic drive to form tumors, maintaining adequate calcium‑vitamin D balance, avoiding smoking, limiting alcohol, and keeping a healthy weight can help reduce complications and support overall endocrine health. Regular follow‑up remains the most important risk‑reduction strategy.
Treatment follows standard protocols for the tumor type (e.g., surgical removal of a parathyroid adenoma or transsphenoidal surgery for a pituitary adenoma). However, because CDKN1B‑related tumors may be more aggressive, clinicians often monitor more closely for recurrence and may consider adjuvant therapies earlier.
Source: MedlinePlus, National Library of Medicine

MedlinePlus brings together authoritative health information from the National Library of Medicine (NLM), the National Institutes of Health (NIH), and other government agencies and health-related organizations.

kontakt@hittavard.se

Ⓒ 2024. Alla rättigheter förbehålls av juxt ab